|Articles|May 21, 2023
Advancing Gene and Cell Therapies for Brain Cancer
Author(s)CGTLive Staff
May is Brain Cancer Awareness Month, and the ACGT is raising awareness of the potential of the human immune system when combined with cell and gene therapy to defeat brain tumors.
Advertisement
Brain cancer is one of the deadliest and most difficult-to-treat cancers. Surgery is difficult due to the sensitivity of the brain, and chemotherapy and radiation have limited effectiveness, in addition to a long list of side effects.
For this reason, many cancer experts, patients, caregivers and more are researching and learning more about cell and gene therapy for brain cancer . This novel type of cancer treatment harnesses the power of our own immune system to fight cancer naturally with less harm to healthy tissue than chemotherapy and radiation.
As May is Brain Cancer Awareness Month, Alliance for Cancer Gene Therapy (ACGT) is spending the month raising awareness of the potential of the human immune system when combined with cell and gene therapy to defeat brain tumors. Scientists can make genetic changes to our immune system to help it find and fight brain cancer cells – creating a “living medicine” that not only can wipe out cancer but also prevent it from returning.
This type of treatment is already FDA-approved for several blood cancers, such as lymphoma and leukemia, and it’s in testing for several types of solid tumors.
In 2001, Alliance for Cancer Gene Therapy (ACGT) was founded as one of the first and only nonprofit organizations committed to pursuing advancements in cancer cell and gene therapy. Over the past 2-plus decades, ACGT has awarded 67 research grants totaling $34.2 million to 63 of the brightest scientists.
The foundation is committed to advancing brain cancer research involving cell and gene therapies by funding scientists who are trying to develop cures for this cancer. Even in the past few years, there has been major progress in developing therapies for brain tumors.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 10, 2025
September 10th 2025
- Trends in RNA Therapeutic Research
September 8th 2025
Advertisement
Advertisement
Trending on CGTlive®
1
Patients Treated With REGENXBIO's MPS II Gene Therapy RGX-121 Sustain 82% Median Reduction in CSF HS D2S6 Levels Through 1 Year
2
Patients With DMD Treated With Avidity Biosciences’ Antibody Oligonucleotide Conjugate Del-Zota Show Functional Improvements
3